ClinicalTrials.gg
CompletedNCT01395888Updated Feb 15, 2018Results posted

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

A Phase 3 interventional study of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) and Tiotropium in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 55 sites in 7 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
83rd of 236
260 · median 101
Started
2011
with 25 others
Phase 3
65 of 276
5 open now
Registered
132nd of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 83rd largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 132nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is designed to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness compared with Tiotropium QD over 12 week treatment period in subjects with COPD and aortic pulse wave velocity (aPWV) > 12.0 m/s at Visit 1. Arterial stiffness will be measured as aPWV. This is a comparator, randomised, double-blind, double-dummy, parallel group, multi-centre study. Subjects who meet the eligibility criteria at Screening and meet the randomization criteria at the end of a 2-week Run-In period will enter a 12-week treatment period. There will be an approximate 7-day Follow-up period after the treatment period.

Read the detailed description

This is a Phase IIIb comparator, double-blind, double-dummy, randomised (1:1), parallel group, multi-centre study. At Visit 1 (Screening Visit), subjects who meet the pre-defined Inclusion Criteria and none of the Exclusion Criteria will enter a 2-week, single-blind placebo Run-in Period. The purpose of the Run-In Period is to monitor albuterol/salbutamol use at baseline, and to ensure that subjects' COPD is at a stable stage at randomization. Subject's adherence with study procedures, diary completion will also be evaluated during the Run-In Period. At the end of the Run-in period, subjects will be assessed and those who meet the randomisation criteria will receive one of the following two double-blind treatments for 12 weeks:

  • FF (100 mcg)/VI (25 mcg) administered QD via a NDPI in the morning
  • Tiotropium (18 mcg) administered QD via a HandiHaler in the morning

To ensure blinding of the treatments and to ensure a double-dummy design matching NDPI and HandiHaler will be utilised. Each subject will be instructed to self administer blinded study drug during the double blind treatment period as follows:

  • Each morning take 1 inhalation from NDPI containing FF (100 mcg)/VI (25 mcg) followed by 1 inhalation from placebo capsule delivered via HandiHaler.
  • Each morning take 1 inhalation from matching placebo NDPI followed by 1 inhalation from a capsule containing tiotropium 18 mcg delivered via HandiHaler.

An inhaled short acting beta2-receptor agonist, salbutamol/albuterol will be provided to subjects to use as needed throughout the Run-in and Treatment periods for relief of COPD symptoms. Ipratropium bromide is permitted if the subject is on a stable dose from Screening (Visit 1) and remains on the stable dose throughout the study. Subjects who experience an exacerbation of their COPD (which requires medication in addition to an increase in rescue medication) or a lower respiratory tract infection (LRTI) during the run-in period are not eligible to enter the treatment period. Any subject who experiences a similar COPD exacerbation (sec 4.4) or LRTI at any time on therapy will be withdrawn from the study. The aPWV will be measured at Screening and clinic Visits 3-5. Disease specific health status will be evaluated using the St. George's Respiratory Questionnaire (SGRQ-C), Euro Qol Questionnaire (EQ-5D) for COPD patients and the COPD Assessment Test (CAT) at Visit 2 (Day 1) and at Visit 5 (Weeks 12). The 12-lead ECG will be evaluated at Visit 1 (Screening) only. Vital signs (blood pressure and pulse rate), spirometry measurements, and clinical laboratory tests (hematology and chemistry) and other study-specific safety assessments will be obtained at selected clinic visits. A follow-up phone call will occur approximately 7 days after the last clinic visit. The overall study duration from Screening to Follow-up for each subject is approximately 15 weeks. Subjects will be considered to have completed the study upon completion of assessments and procedures up to and including completion of Follow-up Phone Contact (7 ± 2 days post Visit 5).

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient
  • : Subjects must give their signed and dated written informed consent to participate.
  • Gender: Male or female subjects.
  • Age: greater then or equal to 40 years of age at Screening (Visit 1)
  • diagnosis: Subjects with a clinical history of COPD in accordance with the following definition by the American Thoracic Society (ATS) /European Respiratory Society(ERS).
  • Subjects with a current or prior history ofgreater then or equal to 10 pack-years of cigarette smoking at Screening (Visit 1).
  • Subjects with a measured post-albuterol/salbutamol less then 70% of predicted at Screening (Visit 1).
  • Subjects with a measured post-albuterol/salbutamol FEV1/FVC ratio of less then or equal to 0.70 at Screening (Visit 1).
  • Exacerbation History: Subjects who have been hospitalised or have been treated with oral or antibiotics for their COPD within the last 3 years prior to Screening (V1).
  • Baseline aPWV: subjects with a measured aPWV greater then 12.0 m/s at Screening (Visit 1).

Exclusion criteria

Exclusion Criteria:

  • of less then or equal to 35
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Relovair

    Inhaled long-acting bronchodilator and corticosteroid combination

    Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)

  • Active comparator
    Tiotropium

    Inhaled long-acting anticholinergic

    Drug: Tiotropium

Interventions

  • Drugfluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)

    fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)

  • • Tiotropium (18 mcg) administered QD via a HandiHaler

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)

    PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of Eh/2pR, where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and p is the blood density. Change from Baseline was calculated as the Day 84 value minus the Baseline value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking status at screening, geographical region, Baseline aPWV, and interaction terms of Baseline by visit and treatment by visit.

    Time frame: Baseline to Day 84 (Early Withdrawal)

07

Results

Posted Aug 9, 2013

Participant flow

A total of 260 participants were randomized. Three of these participants were randomized in error (they were determined not to have met entry criteria and were classified as run-in/screen failures); thus, they did not receive investigational product and are not captured in the Treatment Period table of the Participant Flow module.

2-week Run-in Period
Participant flow — 2-week Run-in Period
MilestoneSalb/Alb + IBrFF/VI 100/25 µgTiotropium Bromide 18 µg
Started27900
Completed25700
Not completed2200
Withdrew: Adverse event200
Withdrew: Continuation criteria not met1300
Withdrew: Lost to follow-up100
Withdrew: Protocol violation200
Withdrew: Withdrawal by subject400
Treatment Period (TP)
Participant flow — Treatment Period (TP)
MilestoneSalb/Alb + IBrFF/VI 100/25 µgTiotropium Bromide 18 µg
Started0127130
Completed the treatment period0112113
Completed0112113
Not completed01517
Withdrew: Adverse event076
Withdrew: Lack of efficacy043
Withdrew: Protocol violation015
Withdrew: Met protocol-defined stopping criteria010
Withdrew: Withdrawal by subject023

Outcome measures

PrimaryMean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)

PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of Eh/2pR, where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and p is the blood density. Change from Baseline was calculated as the Day 84 value minus the Baseline value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking status at screening, geographical region, Baseline aPWV, and interaction terms of Baseline by visit and treatment by visit.

Time frame:
Baseline to Day 84 (Early Withdrawal)
Reported as:
Least squares mean · meters per second (m/sec)
Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)
meters per second (m/sec)FF/VI 100/25 µgTiotropium Bromide 18 µg
Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 12-week Treatment Period (Day 84)-0.859 ± 0.2590-1.118 ± 0.2620
Statistical analysis
  • FF/VI 100/25 µg vs Tiotropium Bromide 18 µg · Mixed Models Analysis · p = 0.484 · Least squares mean difference: 0.259 · 95% CI -0.468 to 0.986Restricted maximum likelihood (REML)-based repeated measures approach (MMRM)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 µg—7/127 (5.5%)8/127 (6.3%)
Tiotropium Bromide 18 µg—8/130 (6.2%)8/130 (6.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventFF/VI 100/25 µgTiotropium Bromide 18 µg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1275/130
PneumoniaInfections and infestations2/1270/130
Acute abdomenGastrointestinal disorders1/1270/130
PancreatolithiasisGastrointestinal disorders1/1270/130
PyrexiaGeneral disorders1/1270/130
Bile duct obstructionHepatobiliary disorders1/1270/130
Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1270/130
Altered state of consciousnessNervous system disorders1/1270/130
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1271/130
Peritonsillar abscessInfections and infestations0/1271/130
Most frequent other events
Most frequent other events
EventFF/VI 100/25 µgTiotropium Bromide 18 µg
NasopharyngitisInfections and infestations5/1274/130
HeadacheNervous system disorders3/1275/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF/VI 100/25 µgTiotropium Bromide 18 µgTotal
Mean66.7 ± 7.2067.7 ± 7.3467.3 ± 7.28
Sex: Female, Male
Sex: Female, Male(Participants)FF/VI 100/25 µgTiotropium Bromide 18 µgTotal
Female191837
Male108112220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)FF/VI 100/25 µgTiotropium Bromide 18 µgTotal
White - White/Caucasian/European127130257
08

Study locations

55 sites
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1056ABJ, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000JKR, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Juan, 5400, Argentina
  • GSK Investigational Site
    Tucuman, 4000, Argentina
  • GSK Investigational Site
    Tucumán, T4000DGF, Argentina
  • GSK Investigational Site
    Bethune Cedex, 62408, France
  • GSK Investigational Site
    Grenoble Cedex 09, 38043, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Montpellier cedex 5, 34295, France
  • GSK Investigational Site
    Reims Cedex, 51092, France
  • GSK Investigational Site
    Saint-Michel, 16470, France
  • GSK Investigational Site
    Immenhausen, Hessen 34376, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Hamburg, 20354, Germany
  • GSK Investigational Site
    Eboli (SA), Campania 84025, Italy
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Crema, Lombardia 26013, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Cassano Murge (BA), Puglia 70020, Italy
  • GSK Investigational Site
    Bergen, 5017, Norway
  • GSK Investigational Site
    Bergen, N-5021, Norway
  • GSK Investigational Site
    Drammen, 3004, Norway
  • GSK Investigational Site
    Fredrikstad, 1606, Norway
  • GSK Investigational Site
    Skedsmokorset, N-2020, Norway
  • GSK Investigational Site
    Chita, 672000, Russian Federation
  • GSK Investigational Site
    Kemerovo, 650002, Russian Federation
  • GSK Investigational Site
    Kokhma, 153511, Russian Federation
  • GSK Investigational Site
    Moscow, 105077, Russian Federation
  • GSK Investigational Site
    Moscow, 115093, Russian Federation
  • GSK Investigational Site
    Penza, 440067, Russian Federation
  • GSK Investigational Site
    Saratov, 410053, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    Vladivostok, Primorskiy Kray, 690022, Russian Federation
  • GSK Investigational Site
    Voronezh, 394018, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150003, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150062, Russian Federation
  • GSK Investigational Site
    Cherkassy, 18009, Ukraine
  • GSK Investigational Site
    Donetsk, 83099, Ukraine
  • GSK Investigational Site
    Kharkiv, 61035, Ukraine
  • GSK Investigational Site
    Kiev, 03680, Ukraine
  • GSK Investigational Site
    Kyiv, 03038, Ukraine
  • GSK Investigational Site
    Kyiv, 03049, Ukraine
  • GSK Investigational Site
    Yalta, 98603, Ukraine
09

References and documents

Publications

  • Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest. 2014 Dec;146(6):1521-1530. doi: 10.1378/chest.13-2859. PubMed 25058845 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year after primary completion. A results delay was requested in Mar 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2011
First posted
Jul 18, 2011
Start
Jun 30, 2011
Primary completionActual
Aug 1, 2012
CompletionActual
Aug 6, 2012
Results delay requested
Mar 7, 2013
Results first posted
Aug 9, 2013
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01395888
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 18, 2011
Start date
Jun 30, 2011
Primary completion
Aug 1, 2012
Completion
Aug 6, 2012
Results posted
Aug 9, 2013
Last update
Feb 15, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion